Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al
- PMID: 31818809
- DOI: 10.1136/annrheumdis-2019-216593
Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al
Keywords: DMARDs (biological); rheumatoid arthritis; treatment.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial.Ann Rheum Dis. 2020 Jan;79(1):94-102. doi: 10.1136/annrheumdis-2019-216169. Epub 2019 Oct 19. Ann Rheum Dis. 2020. PMID: 31630117 Free PMC article. Clinical Trial.
-
Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al.Ann Rheum Dis. 2021 Nov;80(11):e172. doi: 10.1136/annrheumdis-2019-216557. Epub 2019 Nov 19. Ann Rheum Dis. 2021. PMID: 31744825 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
